En Es
Categories

Industry News

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

By Labmedica International staff writers
05 May 2021

Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.

The clinical laboratory has gone through trial by fire in 2020, where total testing was 245% of baseline volumes, with ~55% being SARS-CoV-2 molecular tests. Despite vaccines, many industry players suggest SARS-CoV-2 testing volumes would not be impacted in the near term, and the demand for COVID-19-related testing will continue through 2021 and potentially into 2022. This means that testing-volume pressure on labs is going to continue.

Labs of all sizes are facing the same challenges: shortage of laboratory technologists and technicians, historic financial pressures on hospitals and health systems, and physically and mentally exhausted laboratory professionals - a pre-pandemic problem that has since been exacerbated. However, the TLA solutions that cater to labs processing high-sample volumes are out of reach for smaller volume labs due to space requirements and infrastructure constraints.

With the DxA 5000 Fit, mid-sized labs can enjoy the same benefits as larger-volume lab. The DxA 5000 Fit’s comprehensive workflow automation reduces up to 80% of manual steps through pre-analytical, analytical and post-analytical automation, thereby conserving precious human resources to do higher-value clinical work. It offers intelligent routing with dynamically calculated route planning for rapid and consistent TAT, with STATs always prioritized to deliver results faster. Additionally, its flexible design can be adapted to meet a mid-volume lab's space and infrastructure constraints.

"At Beckman Coulter, we believe that medium-size labs should be able to leverage the benefits of automation to address their challenges. Just because your lab is not processing a higher number of samples, doesn't mean you have to sacrifice the benefits of intelligent laboratory automation and settle for a marginally automated workcell-plus solution," said Dr. Peter Soltani, senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "This is why we have launched DxA 5000 Fit, the first compact workflow automation solution that's the right fit for mid-volume labs because automation should be for all labs."




E-mail Print
FaceBook Twitter Google+ Linked in

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, electrochemistry, immunoassay, hematology and spectrophotometry products among others. The company’s biomedical laboratory instruments and diagnostic solutions, as well as automated and integrated data management systems, are suitable for diagnosing diseases, making treatment decisions and monitoring patients in hospitals and other critical care settings.
More info

More articles about BECKMAN COULTER, INC.

01 Feb 2021
Beckman Coulter Launches New DxH 560 AL Tabletop Hematology Analyzer for Small- and Medium-Sized Labs
Beckman Coulter (Brea, CA, USA) has launched the new DxH 560 AL, a tabletop hematology analyzer geared to reduce the time and resource constraints faced by small to mid-sized laboratories.
Read More
20 May 2019
Beckman Coulter Introduces New Total Laboratory Automation Solution
Beckman Coulter’s latest addition to its automation portfolio, the DxA 5000 total laboratory automation solution has achieved European CE Mark and China Food and Drug Administration approval.
Read More
01 Mar 2019
Beckman Coulter Life Sciences Enters Partnership with Apostle
Beckman Coulter Life Sciences has entered into a partnership with Apostle Inc. for the launch of Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit, a magnetic nanoparticle-based kit to extract circulating free DNA (cfDNA) from plasma using manual or automated workflows.
Read More
23 Jan 2019
Beckman Coulter Launches ClearLLab 10C System for Clinical Flow Cytometry Labs
Beckman Coulter has launched the ClearLLab 10C System for clinical flow cytometry labs that includes the first 10-color CE-IVD panels of immunophenotyping reagents for both lymphoid and myeloid lineages.
Read More

Additional news

06 Dec 2021
IHF to Launch Geneva Centre of Healthcare Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) is preparing to launch the Geneva Centre of Healthcare Leadership for Sustainability (the Centre) in 2022 in response to the need for hospitals and healthcare services to address climate change.
Read More
06 Dec 2021
Global Mammography Market to Reach USD 3.4 Billion in 2028 Due To Increasing Prevalence of Breast Cancer
The global mammography market is expected to reach USD 3.4 billion in 2028, driven by the increasing prevalence of breast cancer across the globe, rising government fund for ongoing research on breast cancer, and increasing public awareness about cancer. The market growth is being fueled further by increasing number of screening programs and campaigns to create awareness about breast cancer, improving healthcare infrastructure and facilities, and technological advancements in breast imaging techniques.
Read More
03 Dec 2021
Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population
The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests by physicians, low price of tests, and awareness about complications of high diabetes levels.
Read More
02 Dec 2021
Roche Completes Acquisition of TIB Molbiol Group
Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
Read More
02 Dec 2021
Siemens Partners with Biotech Company Freenome to Develop Blood Test for Early Breast Cancer Detection
Siemens Healthineers (Erlangen, Germany) and Freenome (South San Francisco, CA, USA) have entered into a collaboration in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Read More
01 Dec 2021
Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing
The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow assay kits, demand growth of point-of-care testing, and rise in adoption of LFA kits due to their advantages over laboratory tests.
Read More
30 Nov 2021
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market to Surpass USD 7.5 Billion by 2025
The global chemiluminescence immunoassay (CLIA) analyzers market is estimated to grow at a CAGR of 6.4% in the forecast period of 2020-2025 to reach USD 7.6 billion by 2025, with the reagents segment anticipated to capture almost three-fourth of the overall CLIA analyzers market and reach USD 5.7 billion by the end of 2025.
Read More
29 Nov 2021
Global Fluoroscopy Equipment Market to Top USD3.5 Billion by 2031 Due to Demand for Multipurpose Imaging Tools
The global fluoroscopy equipment market is projected to grow at a CAGR of 6% from an estimated USD 1.9 billion in 2021 to surpass USD 3.5 billion by the end of 2031, driven by surging applications of fluoroscopy equipment across various medical fields such as cardiology, nephrology, urology, and others.
Read More
25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions